Homology Medicines Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:N/A
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Homology Medicines's estimated annual revenue is currently $3.7M per year.
  • Homology Medicines's estimated revenue per employee is $20,331

Employee Data

  • Homology Medicines has 181 Employees.
  • Homology Medicines grew their employee count by 53% last year.
  • Homology Medicines currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

keywords:N/A

181

Number of Employees

$3.7M

Revenue (est)

1

Current Jobs

53%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Homology Medicines News

09/03/2019 - UPDATE: Baird Starts Homology Medicines (FIXX) at Outperform

Baird analyst Madhu Kumar initiates coverage on Homology Medicines (NASDAQ: FIXX) with a Outperform rating and a price target of $30.00.

09/08/2019 - Here's Why Homology Medicines, Inc. (FIXX) Is A Stock To Set Your Sights On

On Tuesday, shares of Homology Medicines, Inc. (NASDAQ:FIXX) marked $21.70 per share versus a previous $21.06 closing price.

09/03/2019 - Homology Medicines (NASDAQ:FIXX) Coverage Initiated at Robert W. Baird

Research analysts at Robert W. Baird started coverage on shares of Homology Medicines (NASDAQ:FIXX) in a research note issued on ...